Care Bare Rx Review: $300 Sermorelin, Wrong Landing Page

Care Bare Rx does something most of this category will not: it publishes the vial. Its sermorelin is sermorelin acetate 2 mg/mL in a 10 mL vial at $300 a month, month-to-month, with no commitment ladder underneath it — and that figure comes from the company's own product catalogue, served openly, not from a marketing badge.

It also does something we have to warn you about before anything else: the page it sends you to advertises prices its own checkout does not sell.

The price, and where it comes from

Care Bare Rx runs on a white-label telehealth backend shared by several brands we track, and one consequence of that architecture is that its entire catalogue — 22 bundles — is served without a login. So the prices below are facts rather than claims:

• •Sermorelin acetate, 2 mg/mL, 10 mL — $300/month. No three-, six- or twelve-month rung is published for it.
• •NAD+, 200 mg/mL, 10 mL — $325/month.
• •B-12 methylcobalamin, 5 mg/mL — $200/month, the same price at both vial sizes it lists.

Naming the strength matters more than it sounds. "$300 for sermorelin" is not comparable to anything; "$300 for 20 mg of sermorelin acetate" is, and most of the market will not give you the second version. Set against the wider range in what sermorelin costs per month, $300 is at the top end — but it is one of the few figures on our board attached to a stated quantity, and there is no prepay ladder to step off and no intro rate that expires.

Two conditions travel with it. An $80 telehealth consultation fee applies if you complete a visit and no medication is prescribed — a condition that appears in the catalogue copy rather than on any marketing page. And the terms state that consult fees are not refundable and that all sales are final.

The landing-page problem, stated plainly

The page Care Bare Rx's affiliate link delivers you to is not the page its checkout agrees with. That lander advertises a set of prices — for a branded GLP-1, for its hair line, for its sexual-health line — that are lower than the ones on the company's own about and FAQ pages, and it is those latter pages that match what the checkout will actually charge you.

We checked whether we could point our link somewhere better. We cannot: with no landing-page selector and with the one the affiliate programme provisions, the link resolves to the same lander either way. So rather than quietly send readers to it, we are telling you what it is. If a number on the page you land on looks better than the numbers on the same company's about page, the about page is the one to believe.

There is a second version of the same defect that is worth knowing because it touches the longevity line directly. A banner reading "NAD+ therapy from $199/mo" runs on every page of the site. There is exactly one NAD+ product in the catalogue and it is $325. The $199 is purchasable at no tier at all — it is not a first-month rate, not a prepay rung, not a smaller vial. It matches nothing.

And on its GLP-1 page, three-month bundle totals are labelled "/mo": a bundle shown as "from $748/mo" is $748 for three months, or about $249 a month. That is arithmetic in the buyer's favour once you spot it, and against them if they do not.

The pharmacies and the prescribers — better than we first credited

Care Bare Rx's disclosure here is genuinely strong, and stronger than our first pass gave it credit for. Its FAQ names four dispensing pharmacies — Belmar, with full street addresses, plus Strive, Epiq Scripts and Casa Pharma Rx — and four prescribing clinicians with NPIs: Dr Ana Lisa Carr MD (1689841744), Dr Kelly Tenbrink MD (1346482684), Dr Italia (1487815387) and Dr Mansour (1689164949). Only seven rows on our sermorelin board name a dispensing pharmacy at all, and this is one of them.

One qualifier travels with it, and it is the honest way to read the whole thing. That copy is shared. Care Bare Rx runs on a white-label telehealth backend, and the same four pharmacies, the same clinicians and the same wording appear byte for byte on every other brand running it. The disclosure is real — those pharmacies genuinely fill these prescriptions and those NPIs check out — but it describes the platform, not this brand. Finding the same names on four storefronts is one confirmation repeated, not four independent ones, and no brand here corroborates its siblings.

One thing to be precise about in the other direction, since it is easy to over-credit: Care Bare's only mention of 503A is a general compliance sentence about state boards regulating 503A pharmacies. That is not a claim that its own pharmacies are 503A, and we do not treat it as one.

Which brings us to the pharmacy that has to be disclosed. One of the four is Belmar.

So, disclosed rather than buried: the FDA issued a warning letter to `Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy` in March 2023, and that letter was closed out on 30 October 2023.¹ Closed out means the agency has recorded that the matters raised were addressed. We are not restating what the letter said — that is the agency's account to give, and it is on the agency's own index, linked in our references. We state that it exists, who it was addressed to, when, and that it is closed, because a reader clicking through to a service that names this pharmacy should hear it from us rather than find it later.

Care Bare Rx itself has no warning letter. We screened the company, its backend operator and its trading names against the FDA's database on 8 August 2026, on a search validated against a known positive in the same pass, and found nothing on record for any of them. Its other named pharmacies came back clean too.

Where it ships, which its own pages disagree about

Care Bare Rx's FAQ says it serves all 50 states and Puerto Rico. Its own product copy says something different: the B-12 line carries a no-ship list of eleven states, and NAD+ in those same eleven states is filled by secondary pharmacies at a cost that "may vary".

Both halves matter. The wellness line is not a 50-state product, and in eleven states the NAD+ price is not the published price. If you live in one of them, ask what you will actually be charged before you start — and read our note on how to get a sermorelin prescription for what a legitimate state-licensed route is supposed to look like.

What sermorelin will and will not do for you here

None of the above changes the pharmacology, and neither does the price. Sermorelin is GHRH(1-29): it prompts your own pituitary to release growth hormone in pulses rather than replacing the hormone, and it raises GH and IGF-1 reliably in the short term²³. The sleep effect that brings most readers to this site is real and it is measured — GHRH increases slow-wave sleep in healthy men alongside the GH pulse⁴ — and GHRH's role in sleep regulation is well described⁵.

What does not exist is a long-term outcome trial in healthy adults⁶, and there is no FDA-approved finished sermorelin product on the US market, so every legitimate prescription is compounded⁷. Care Bare Rx does not require bloodwork to start, which is convenient and also means starting a growth-hormone-axis therapy with no baseline IGF-1 to measure against. Getting one drawn yourself is cheap insurance — sermorelin labs and IGF-1 monitoring covers what to ask for.

Who it suits

It suits someone who wants a named strength at a flat month-to-month price and is prepared to pay toward the top of the range for it; who values four named pharmacies and four named prescribers with NPIs over an anonymous "licensed US compounder", while understanding that those names belong to the platform rather than to this brand alone; and who is going in knowing that the page they landed on is not the page the checkout obeys.

It suits you less if $300 a month is the deciding factor — our price-sorted board has several verified programmes well below it — if you live in one of the eleven states where its wellness pricing goes soft, or if the $80 not-prescribed fee is a risk you do not want on a therapy you may well not be approved for.

Bottom line

$300 a month for sermorelin acetate 2 mg/mL in a 10 mL vial, month-to-month, no ladder — a real price for a named quantity, which is rarer than it should be — alongside four named pharmacies and four prescribers with verifiable NPIs, which is rarer still, provided you read them as facts about the shared platform rather than about this brand. Around it: a landing page advertising prices the checkout does not honour, an NAD+ banner matching no tier, bundle totals labelled per month, an $80 fee if nothing is prescribed, an all-sales-final policy, and a 50-state claim its own product copy contradicts eleven times over. One of its named pharmacies carries a March 2023 FDA warning letter that was closed out in October 2023. Buy on the about-page prices, not the lander's, and confirm your state before you pay.